Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE

MoonLake Immunotherapeutics

Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.
PIPE of $115M at $10.00/share from investors including sponsor affiliate and existing MoonLake holders.
Combined company to rename as MoonLake Immunotherapeutics; Helix Class B shares convert to Class A 1:1.
Closing expected late Q4 2021/early Q1 2022, subject to shareholder approvals and minimum $150M cash condition.
Post-closing board: 7 directors (4 designated by MoonLake, 2 by Helix, plus Jorge Santos da Silva).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.